237 related articles for article (PubMed ID: 34261799)
21. Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Nowak A; Dziedzic T; Czernicki T; Kunert P; Morawski K; Niemczyk K; Marchel A
Neurol Neurochir Pol; 2015; 49(5):295-301. PubMed ID: 26377980
[TBL] [Abstract][Full Text] [Related]
22. Auditory outcomes in tumor vs. nontumor patients fitted with auditory brainstem implants.
Colletti V
Adv Otorhinolaryngol; 2006; 64():167-185. PubMed ID: 16891842
[TBL] [Abstract][Full Text] [Related]
23. Management of hearing in pediatric NF2.
Shepard TH; Tucci DL; Grant GA; Kaylie DM
Otol Neurotol; 2012 Aug; 33(6):1066-70. PubMed ID: 22710553
[TBL] [Abstract][Full Text] [Related]
24. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Zhao Y; Cao J; Melamed A; Worley M; Gockley A; Jones D; Nia HT; Zhang Y; Stylianopoulos T; Kumar AS; Mpekris F; Datta M; Sun Y; Wu L; Gao X; Yeku O; Del Carmen MG; Spriggs DR; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2210-2219. PubMed ID: 30659155
[TBL] [Abstract][Full Text] [Related]
25. Neurofibromatosis type 2: Hearing preservation and rehabilitation.
Jia H; El Sayed MME; Smail M; Mosnier I; Wu H; Sterkers O; Kalamarides M; Bernardeschi D
Neurochirurgie; 2018 Nov; 64(5):348-354. PubMed ID: 30314805
[TBL] [Abstract][Full Text] [Related]
26. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.
Plotkin SR; Merker VL; Muzikansky A; Barker FG; Slattery W
Otol Neurotol; 2014 Jan; 35(1):e50-6. PubMed ID: 24335938
[TBL] [Abstract][Full Text] [Related]
27. Cochlear implants in the management of hearing loss in Neurofibromatosis Type 2.
Harris F; Tysome JR; Donnelly N; Durie-Gair J; Crundwell G; Tam YC; Knight RD; Vanat ZH; Folland N; Axon P
Cochlear Implants Int; 2017 May; 18(3):171-179. PubMed ID: 28335700
[TBL] [Abstract][Full Text] [Related]
28. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
29. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma.
Lustig LR; Yeagle J; Driscoll CL; Blevins N; Francis H; Niparko JK
Otol Neurotol; 2006 Jun; 27(4):512-8. PubMed ID: 16791043
[TBL] [Abstract][Full Text] [Related]
30. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
31. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
Miyakawa T; Kamada N; Kobayashi T; Hirano K; Fujii K; Sasahara Y; Nagai Y; Shinkai H
J Dermatol; 2007 Jan; 34(1):60-4. PubMed ID: 17204104
[TBL] [Abstract][Full Text] [Related]
34. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
35. Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.
Zhao F; Wang B; Yang Z; Zhou Q; Li P; Wang X; Zhang J; Zhang J; Liu P
J Neurooncol; 2018 Jun; 138(2):417-424. PubMed ID: 29492767
[TBL] [Abstract][Full Text] [Related]
36. Ipsilateral cochlear implantation in patients with sporadic vestibular schwannoma in the only or best hearing ear and in patients with NF2.
Lassaletta L; Aristegui M; Medina M; Aranguez G; Pérez-Mora RM; Falcioni M; Gavilán J; Piazza P; Sanna M
Eur Arch Otorhinolaryngol; 2016 Jan; 273(1):27-35. PubMed ID: 25537817
[TBL] [Abstract][Full Text] [Related]
37. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of hearing loss in neurofibromatosis type 2.
Asthagiri AR; Vasquez RA; Butman JA; Wu T; Morgan K; Brewer CC; King K; Zalewski C; Kim HJ; Lonser RR
PLoS One; 2012; 7(9):e46132. PubMed ID: 23049959
[TBL] [Abstract][Full Text] [Related]
39. Audiologic presentation of vestibular schwannomas in neurofibromatosis type 2.
Lalwani AK; Abaza MM; Makariou EV; Armstrong M
Am J Otol; 1998 May; 19(3):352-7. PubMed ID: 9596188
[TBL] [Abstract][Full Text] [Related]
40. Comparison of outcomes of peripheral nerve schwannoma excision in neurofibromatosis type 2 patients and non-neurofibromatosis type 2 patients: A case control study.
Bendon CL; Furniss D; Giele HP
J Plast Reconstr Aesthet Surg; 2015 Sep; 68(9):1199-203. PubMed ID: 26139580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
